Financial Data and Key Metrics Changes - The company recorded revenues of $7.6 million for the current quarter, representing over a 1,100% increase from two years ago [36] - Revenue growth is now more diversified, with 56% from the construction segment and 44% from the medical segment [36] - The company has a healthy balance sheet with over $2.4 million in cash and low debt levels, providing a runway for significant growth [40][41] Business Line Data and Key Metrics Changes - The construction segment has grown significantly, contributing 56% of total revenues, while the medical segment contributed 44% [36] - The company has transitioned from being heavily reliant on COVID testing to a more balanced revenue stream, with a focus on point-of-care solutions [38][39] Market Data and Key Metrics Changes - The company is targeting large verticals, including a $90 billion commercial construction market and an $85 billion global modular construction market [23] - The multifamily housing market is expected to see $213 billion in investment in 2022 alone [23] Company Strategy and Development Direction - The company aims to create a diverse revenue stream through its development company, SG Development Corp, which has a residential pipeline of over 4,100 homes and apartments [44][47] - The strategy includes vertical integration to maximize benefits from modular construction and to avoid additional transportation costs [46] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the need for flexibility in operations due to potential labor issues and rising material costs in the construction industry [65] - The company is optimistic about transitioning from COVID-related revenues to more stable and predictable revenue streams in the medical sector [86] Other Important Information - The company has executed a letter of intent with Teamsters 848 to provide point-of-care testing and lab services, indicating a shift towards more sustainable healthcare solutions [61][62] - The company is focused on maintaining a strong capital allocation strategy and has announced a share buyback plan [42] Q&A Session Summary Question: Future expansion sectors beyond fast food - The company has seen success in the quick-serve restaurant space and is exploring opportunities in food halls and food courts [54][56] Question: Revenue concentration risk - Management is aware of revenue concentration from a single client and is working to diversify revenue streams while maintaining a focus on point-of-care medicine [58][60] Question: Adjustments due to industry shifts - Management is prepared to adapt to changes in the construction industry, including supply chain issues and inflation, and has no major supply chain problems currently [65][66] Question: Stock price movement - The stock has fluctuated between $1.50 and $9, and management believes the company's strong fundamentals will eventually reflect in the stock price [68][70] Question: Potential new verticals for expansion - The company is considering entering the environmental space, particularly in medical waste management, as a new market opportunity [72][73] Question: Revenue and market cap relationship - Management acknowledges the complexity of the market cap situation and is focused on operational growth and transitioning to new revenue streams [99][100]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-38037 SG BLOCKS, INC. (Exact name of registrant as specified in its charter) | Delaware | 95-4463937 | | --- | -- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-38037 SG BLOCKS, INC. (Exact name of registrant as specified in its charter) | Delaware | 95-4463937 | | --- | - ...

SG Blocks, Inc. (NASDAQ:SGBX) Q4 2021 Earnings Conference Call April 18, 2022 4:30 PM ET Company Participants Stephanie Prince - PCG Advisory Paul Galvin - Chairman and Chief Executive Officer Gerald Sheeran - Acting Chief Financial Officer Conference Call Participants Operator Good day and welcome to SG Blocks Fourth Quarter and Year-End 2021 Earnings Conference Call and Webcast. Today’s conference call is being recorded. At this time, I would like to turn the conference over to Stephanie Prince of PCG Adv ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-38037 SG BLOCKS, INC. (Exact name of registrant as specified in its charter) | Delaware | 95-4463937 | | --- | --- | ...

Financial Data and Key Metrics Changes - Year-to-date revenue through September 2021 totaled approximately $29.9 million, a staggering 2,000% increase from the previous year, indicating significant transformation over the past 18 months [6] - Revenue for the third quarter of 2021 was approximately $8.8 million compared to approximately $576,000 for the third quarter of 2020 [26] - Net loss attributed to common shareholders for the third quarter of 2021 was approximately $3.8 million or negative $0.43 per share, compared to a net loss of approximately $1.5 million or negative $0.17 per share in the same quarter of 2020 [26][27] Business Line Data and Key Metrics Changes - In the healthcare vertical, medical testing and services revenue totaled approximately $8.15 million for the third quarter, demonstrating a consistent demand for services [17] - Manufacturing revenue for the third quarter totaled approximately $682,000, a 16% increase from the same quarter last year [19] - The company is under contract for six manufacturing projects outside of legacy projects, representing $1.5 million in potential gross revenues over the next two quarters [19] Market Data and Key Metrics Changes - The company has a pipeline that includes 2,250 residential units for sale or rent, representing approximately $367 million of gross potential manufacturing revenue over the next 4 to 5 years [9] - The company is committed to expanding affordable housing solutions, particularly in light of rising home prices [56] Company Strategy and Development Direction - The company plans to build and deploy mobile CLIA-certified laboratories for point-of-care testing, indicating a focus on healthcare solutions [9] - The company has expanded its manufacturing capacity significantly, with plans to increase output by five times through new facilities [10] - The company aims to achieve cash flow positivity during the fourth quarter of 2021 and continues to focus on driving revenue growth [6][12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the strong revenue growth and the potential for continued expansion in various verticals [31] - The company is closely monitoring supply chain issues and is managing its operations with a focus on maintaining delivery schedules [53] - Management emphasized the importance of affordable housing and the company's commitment to addressing this need in the market [56] Other Important Information - The company completed a public offering resulting in net proceeds of approximately $10.5 million, which will support growth and mitigate supply chain issues [12] - The company has entered into long-term employment agreements with key executives to ensure stability and continuity in leadership [13] Q&A Session Summary Question: Any updates on the EV deal with Blink? - Management stated there is no current update but is working closely with Blink on potential deployments and expects more information in the fourth quarter [34] Question: How does the infrastructure bill impact SG Blocks? - Management agreed that investments in infrastructure will require addressing EV and related technologies, which the company is prepared for [35] Question: What is the company doing to reflect its progress in the share price? - Management is focused on driving revenue growth and achieving cash flow positivity, believing that strong fundamentals will create shareholder value [39] Question: Why did the stock price drop from 2017 levels? - Management noted that the stock price in 2017 was an outlier and emphasized the consistent growth in revenue since then [43][44] Question: Current container situation and its impact? - Management reported no issues with container access and is actively managing supply chain challenges [53] Question: Long-term outlook for affordable housing amidst rising prices? - Management reaffirmed commitment to expanding affordable housing solutions, indicating a strong market demand [56]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-38037 SG BLOCKS, INC. (Exact name of registrant as specified in its charter) | Delaware | 95-4463937 | | --- ...

SG Blocks, Inc. (NASDAQ:SGBX) Q2 2021 Earnings Conference Call August 16, 2021 4:30 AM ET Company Participants Stephen Swett - IR Paul Galvin - Chairman and CEO Gerald Sheeran - Acting CFO Conference Call Participants Operator Today and welcome to SG Blocks Second Quarter 2021 Earnings Conference Call and Webcast. Today's conference call is being recorded. At this time, I would like to turn the call over to Stephen Swett of investor relations. Thank you, you may begin. Stephen Swett Good afternoon. Thank yo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-38037 SG BLOCKS, INC. (Exact name of registrant as specified in its charter) | Delaware | 95-4463937 | | --- | -- ...

PART I. FINANCIAL INFORMATION [Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) SG Blocks reported a significant revenue increase to $9.2 million, primarily from new medical services, despite a widened net loss of $2.0 million [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets slightly increased to $27.2 million, with cash decreasing to $10.5 million, while total liabilities rose to $9.0 million Condensed Consolidated Balance Sheet Highlights (Unaudited) | Balance Sheet Item | March 31, 2021 ($) | December 31, 2020 ($) | | :--- | :--- | :--- | | **Current Assets** | | | | Cash and cash equivalents | 10,540,290 | 13,010,356 | | Accounts receivable, net | 3,216,907 | 2,635,608 | | Total current assets | 17,844,168 | 18,298,019 | | **Total Assets** | **27,248,284** | **26,882,098** | | **Current Liabilities** | | | | Accounts payable and accrued expenses | 6,024,738 | 3,961,961 | | Total current liabilities | 7,812,586 | 7,234,681 | | **Total Liabilities** | **8,965,187** | **8,444,275** | | **Total Stockholders' Equity** | **18,283,097** | **18,437,823** | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Total revenue surged to $9.2 million, driven by medical services, but increased operating expenses led to a widened net loss of $2.0 million Condensed Consolidated Statements of Operations (Unaudited) | Line Item | Three Months Ended Mar 31, 2021 ($) | Three Months Ended Mar 31, 2020 ($) | | :--- | :--- | :--- | | **Total Revenue** | **9,187,627** | **198,756** | | Construction services | 3,137,715 | 89,341 | | Medical revenue | 5,955,963 | — | | **Gross Profit** | **1,208,181** | **45,981** | | Total Operating Expenses | 2,369,638 | 795,460 | | **Operating Loss** | **(1,161,457)** | **(749,479)** | | **Net Loss** | **(1,144,350)** | **(747,427)** | | Net loss attributable to common stockholders | (2,033,877) | (747,427) | | **Net Loss Per Share (Basic & Diluted)** | **(0.23)** | **(0.64)** | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities increased to $2.2 million, leading to a $2.5 million decrease in cash, ending at $10.5 million Condensed Consolidated Statements of Cash Flows Summary (Unaudited) | Cash Flow Activity | Three Months Ended Mar 31, 2021 ($) | Three Months Ended Mar 31, 2020 ($) | | :--- | :--- | :--- | | Net cash used in operating activities | (2,183,116) | (1,026,812) | | Net cash used in investing activities | (990,388) | (400,000) | | Net cash provided by financing activities | 703,438 | 199,878 | | **Net decrease in cash and cash equivalents** | **(2,470,066)** | **(1,226,934)** | | Cash and cash equivalents - end of period | 10,540,290 | 398,737 | [Notes to Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail business expansion into medical services and modular manufacturing, a $22.9 million construction backlog, ongoing legal proceedings, and a subsequent land acquisition - The company has diversified its business, adding a significant medical revenue stream through a joint venture with Clarity Lab Solutions for COVID-19 testing and forming Chicago Airport Testing LLC (CAT)[24](index=24&type=chunk)[25](index=25&type=chunk)[48](index=48&type=chunk) - The company's construction backlog was approximately **$22.9 million** as of March 31, 2021, with **$10.0 million** expected to convert to revenue within one year and **$12.9 million** within one to two years[31](index=31&type=chunk)[115](index=115&type=chunk)[118](index=118&type=chunk) Revenue by Customer Type (Q1 2021 vs Q1 2020) | Revenue Category | Q1 2021 ($) | Q1 2020 ($) | | :--- | :--- | :--- | | Construction and Engineering Services | 3,231,664 | 198,756 | | Medical Revenue (lab testing, kit sales) | 5,955,963 | — | | **Total Revenue** | **9,187,627** | **198,756** | - The company is involved in several legal proceedings, including litigation with Pizzarotti, Teton Buildings, HOLA Community Partners, and a former employee. The company is unable to predict the outcome or potential loss and has not recorded any provisions for these matters[151](index=151&type=chunk)[158](index=158&type=chunk)[164](index=164&type=chunk) - Subsequent to the quarter's end, the company acquired a **50-acre** site in Lago Vista, Texas for **$3.5 million** in cash, planning to develop a condominium project[181](index=181&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=38&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Result%20of%20Operations) Management attributes a **4,523%** revenue increase to the new medical segment, despite a gross profit margin decline to **13.2%** and an Adjusted EBITDA loss of **$1.5 million** - The company's business model has evolved to include a royalty fee model for residential construction, direct project-based construction, and a new, rapidly growing medical segment focused on COVID-19 diagnostic services[186](index=186&type=chunk)[187](index=187&type=chunk) - Total revenue for Q1 2021 was **$9,187,627**, an increase of **$8,988,871 (4523%)** from Q1 2020, primarily driven by approximately **$5.9 million** in new medical revenue[195](index=195&type=chunk) - Gross profit margin decreased to **13.2%** in Q1 2021 from **23.1%** in Q1 2020, primarily due to a **$1.0 million** loss on a legacy contract from the SG Echo acquisition[198](index=198&type=chunk) - The company had a cash balance of **$10,540,290** as of March 31, 2021, and management anticipates this is sufficient to fund operations for at least the next twelve months[214](index=214&type=chunk) Non-GAAP Reconciliation: Net Loss to Adjusted EBITDA | Metric | Three Months Ended Mar 31, 2021 ($) | Three Months Ended Mar 31, 2020 ($) | | :--- | :--- | :--- | | Net loss | (2,033,877) | (747,427) | | EBITDA (non-GAAP) | (1,909,191) | (702,078) | | **Adjusted EBITDA (non-GAAP)** | **(1,541,786)** | **(526,576)** | [Quantitative and Qualitative Disclosures About Market Risk](index=49&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This section is not applicable to the company - Not applicable[244](index=244&type=chunk) [Controls and Procedures](index=49&type=section&id=Item%204.%20Controls%20and%20Procedures) Disclosure controls and procedures were deemed ineffective due to a material weakness in financial reporting, with remediation efforts underway including hiring senior accounting personnel - Management concluded that disclosure controls and procedures were **not effective** as of the end of the period[245](index=245&type=chunk) - A material weakness was identified related to the timely closing of accounting records and technical accounting for complex transactions[247](index=247&type=chunk) - Remediation steps include hiring two additional senior accounting personnel to strengthen the financial closing process and oversight[249](index=249&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=51&type=section&id=Item%201.%20Legal%20Proceedings) Information regarding legal proceedings is incorporated by reference from Note 16 of the financial statements - Information regarding legal proceedings is incorporated by reference from "Note 16 - Commitments and Contingencies" in the financial statements section of the report[253](index=253&type=chunk) [Risk Factors](index=51&type=section&id=Item%201A.%20Risk%20Factors) Key risks include a going concern doubt due to historical losses, significant customer concentration, the non-guaranteed nature of the $22.9 million backlog, and potential stockholder dilution - The company's history of losses and cash usage raises substantial doubt about its ability to continue as a going concern if it cannot increase sales or raise additional capital[255](index=255&type=chunk)[256](index=256&type=chunk) - Significant customer concentration risk exists, as two customers generated approximately **80%** of total revenue for the three months ended March 31, 2021[257](index=257&type=chunk) - The construction backlog of **$22.9 million** as of March 31, 2021 is not necessarily indicative of future revenues, as contracts can be canceled, terminated, or suspended at the customer's discretion[259](index=259&type=chunk) - There is a risk of dilution for existing stockholders due to a significant number of outstanding options, warrants, and restricted stock units[261](index=261&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=53&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered sales of equity securities have been reported that were not previously disclosed - None that have not been previously disclosed[263](index=263&type=chunk) [Defaults Upon Senior Securities](index=53&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reports no defaults upon senior securities - None[264](index=264&type=chunk) [Mine Safety Disclosures](index=53&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This section is not applicable to the company - Not applicable[265](index=265&type=chunk) [Other Information](index=53&type=section&id=Item%205.%20Other%20Information) No information was provided under this item [Exhibits](index=54&type=section&id=Item%206.%20Exhibits) This section provides an index of exhibits filed with the Form 10-Q, including corporate governance documents and officer certifications - The report includes certifications by the CEO and CFO pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of 2002[268](index=268&type=chunk)